WAM
AVDL

Wolverine Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Wolverine Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,200
Closed -$202K – 1570
2024
Q4 		$202K Sell
19,200
-1,400
-7% -$17K ﹤0.01% 1020
2024
Q3 		$270K Hold
20,600
– – ﹤0.01% 982
2024
Q2 		$290K Buy
+20,600
New +$336K ﹤0.01% 941
2024
Q1 		– Sell
-24,600
Closed -$347K – 1673
2023
Q4 		$347K Hold
24,600
– – ﹤0.01% 954
2023
Q3 		$253K Hold
24,600
– – ﹤0.01% 1017
2023
Q2 		$405K Buy
+24,600
New +$320K ﹤0.01% 886
2021
Q1 		– Sell
-16,100
Closed -$107K – 2016
2020
Q4 		$107K Sell
16,100
-2,700
-14% -$16.9K ﹤0.01% 1212
2020
Q3 		$94K Buy
+18,800
New +$137K ﹤0.01% 1149

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wolverine Asset Management's AVDL Position: Q1 2025 in Review

Wolverine Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 940 shares — an estimated $9.88K sold.

Wolverine Asset Management first reported a position in AVDL in Q2 2014 and held it in 12 quarters. The position peaked at $97.4K in Q2 2023. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Wolverine Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 940 Avadel Pharmaceuticals shares in Q1 2025, an estimated $9.88K.
  • Wolverine Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 12 quarters.
  • Wolverine Asset Management's Avadel Pharmaceuticals position peaked at $97.4K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.